CREB3L2 and Alzheimer disease: Because CREB3L2-ATF4 interacts with a substantial subset of the AD transcriptome and recapitulates aspects of disease progression, disrupting its activity may mitigate the detrimental effects mediated by Aβ42 and hence potentially improve disease outcomes.